Potent and selective agonism of the melanocortin receptor 4 with mk-0493 does not induce weight loss in obese human subjects: Energy intake predicts lack of weight loss efficacy

R. Krishna, B. Gumbiner, C. Stevens, B. Musser, M. Mallick, S. Suryawanshi, L. Maganti, H. Zhu, T. H. Han, L. Scherer, B. Simpson, D. Cosgrove, K. Gottesdiener, J. Amatruda, Barbara Jean Rolls, J. Blundell, G. A. Bray, K. Fujioka, S. B. Heymsfield, J. A. WagnerG. A. Herman

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

MK-0493 is a novel, potent, and selective agonist of the melanocortin receptor 4 (MC4R), one of the best-validated genetic targets and considered one of the most promising for the development of antiobesity therapeutics. An ad libitum energy-intake model was qualified with excellent reproducibility: the geometric mean ratio (GMR) with 95% confidence interval (CI) for total energy intake over a period of 24 h for 30 mg sibutramine/placebo was 0.82 (0.76, 0.88), and for 10 mg sibutramine/placebo it was 0.98 (0.91, 1.05). MK-0493 showed a small and marginally significant effect on 24-h energy intake, whereas 30 mg of sibutramine caused a significant reduction in total 24-h energy intake; specifically, the GMR (95% CI) for 30 mg sibutramine/placebo was 0.79 (0.74, 0.85). MK-0493 was associated with modest weight reduction from baseline but had only small, statistically insignificant effects relative to placebo after 12 weeks in a fixed-dose study and also after 18 weeks of stepped-titration dosing. We conclude that agonism of MC4R is not likely to represent a viable approach to the development of antiobesity therapeutics.

Original languageEnglish (US)
Pages (from-to)659-666
Number of pages8
JournalClinical pharmacology and therapeutics
Volume86
Issue number6
DOIs
StatePublished - Sep 10 2009

Fingerprint

sibutramine
Receptor, Melanocortin, Type 4
Energy Intake
Weight Loss
Placebos
Confidence Intervals
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Krishna, R. ; Gumbiner, B. ; Stevens, C. ; Musser, B. ; Mallick, M. ; Suryawanshi, S. ; Maganti, L. ; Zhu, H. ; Han, T. H. ; Scherer, L. ; Simpson, B. ; Cosgrove, D. ; Gottesdiener, K. ; Amatruda, J. ; Rolls, Barbara Jean ; Blundell, J. ; Bray, G. A. ; Fujioka, K. ; Heymsfield, S. B. ; Wagner, J. A. ; Herman, G. A. / Potent and selective agonism of the melanocortin receptor 4 with mk-0493 does not induce weight loss in obese human subjects : Energy intake predicts lack of weight loss efficacy. In: Clinical pharmacology and therapeutics. 2009 ; Vol. 86, No. 6. pp. 659-666.
@article{79ca681fc6694a8c8f531082d51f1bae,
title = "Potent and selective agonism of the melanocortin receptor 4 with mk-0493 does not induce weight loss in obese human subjects: Energy intake predicts lack of weight loss efficacy",
abstract = "MK-0493 is a novel, potent, and selective agonist of the melanocortin receptor 4 (MC4R), one of the best-validated genetic targets and considered one of the most promising for the development of antiobesity therapeutics. An ad libitum energy-intake model was qualified with excellent reproducibility: the geometric mean ratio (GMR) with 95{\%} confidence interval (CI) for total energy intake over a period of 24 h for 30 mg sibutramine/placebo was 0.82 (0.76, 0.88), and for 10 mg sibutramine/placebo it was 0.98 (0.91, 1.05). MK-0493 showed a small and marginally significant effect on 24-h energy intake, whereas 30 mg of sibutramine caused a significant reduction in total 24-h energy intake; specifically, the GMR (95{\%} CI) for 30 mg sibutramine/placebo was 0.79 (0.74, 0.85). MK-0493 was associated with modest weight reduction from baseline but had only small, statistically insignificant effects relative to placebo after 12 weeks in a fixed-dose study and also after 18 weeks of stepped-titration dosing. We conclude that agonism of MC4R is not likely to represent a viable approach to the development of antiobesity therapeutics.",
author = "R. Krishna and B. Gumbiner and C. Stevens and B. Musser and M. Mallick and S. Suryawanshi and L. Maganti and H. Zhu and Han, {T. H.} and L. Scherer and B. Simpson and D. Cosgrove and K. Gottesdiener and J. Amatruda and Rolls, {Barbara Jean} and J. Blundell and Bray, {G. A.} and K. Fujioka and Heymsfield, {S. B.} and Wagner, {J. A.} and Herman, {G. A.}",
year = "2009",
month = "9",
day = "10",
doi = "10.1038/clpt.2009.167",
language = "English (US)",
volume = "86",
pages = "659--666",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

Krishna, R, Gumbiner, B, Stevens, C, Musser, B, Mallick, M, Suryawanshi, S, Maganti, L, Zhu, H, Han, TH, Scherer, L, Simpson, B, Cosgrove, D, Gottesdiener, K, Amatruda, J, Rolls, BJ, Blundell, J, Bray, GA, Fujioka, K, Heymsfield, SB, Wagner, JA & Herman, GA 2009, 'Potent and selective agonism of the melanocortin receptor 4 with mk-0493 does not induce weight loss in obese human subjects: Energy intake predicts lack of weight loss efficacy', Clinical pharmacology and therapeutics, vol. 86, no. 6, pp. 659-666. https://doi.org/10.1038/clpt.2009.167

Potent and selective agonism of the melanocortin receptor 4 with mk-0493 does not induce weight loss in obese human subjects : Energy intake predicts lack of weight loss efficacy. / Krishna, R.; Gumbiner, B.; Stevens, C.; Musser, B.; Mallick, M.; Suryawanshi, S.; Maganti, L.; Zhu, H.; Han, T. H.; Scherer, L.; Simpson, B.; Cosgrove, D.; Gottesdiener, K.; Amatruda, J.; Rolls, Barbara Jean; Blundell, J.; Bray, G. A.; Fujioka, K.; Heymsfield, S. B.; Wagner, J. A.; Herman, G. A.

In: Clinical pharmacology and therapeutics, Vol. 86, No. 6, 10.09.2009, p. 659-666.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Potent and selective agonism of the melanocortin receptor 4 with mk-0493 does not induce weight loss in obese human subjects

T2 - Energy intake predicts lack of weight loss efficacy

AU - Krishna, R.

AU - Gumbiner, B.

AU - Stevens, C.

AU - Musser, B.

AU - Mallick, M.

AU - Suryawanshi, S.

AU - Maganti, L.

AU - Zhu, H.

AU - Han, T. H.

AU - Scherer, L.

AU - Simpson, B.

AU - Cosgrove, D.

AU - Gottesdiener, K.

AU - Amatruda, J.

AU - Rolls, Barbara Jean

AU - Blundell, J.

AU - Bray, G. A.

AU - Fujioka, K.

AU - Heymsfield, S. B.

AU - Wagner, J. A.

AU - Herman, G. A.

PY - 2009/9/10

Y1 - 2009/9/10

N2 - MK-0493 is a novel, potent, and selective agonist of the melanocortin receptor 4 (MC4R), one of the best-validated genetic targets and considered one of the most promising for the development of antiobesity therapeutics. An ad libitum energy-intake model was qualified with excellent reproducibility: the geometric mean ratio (GMR) with 95% confidence interval (CI) for total energy intake over a period of 24 h for 30 mg sibutramine/placebo was 0.82 (0.76, 0.88), and for 10 mg sibutramine/placebo it was 0.98 (0.91, 1.05). MK-0493 showed a small and marginally significant effect on 24-h energy intake, whereas 30 mg of sibutramine caused a significant reduction in total 24-h energy intake; specifically, the GMR (95% CI) for 30 mg sibutramine/placebo was 0.79 (0.74, 0.85). MK-0493 was associated with modest weight reduction from baseline but had only small, statistically insignificant effects relative to placebo after 12 weeks in a fixed-dose study and also after 18 weeks of stepped-titration dosing. We conclude that agonism of MC4R is not likely to represent a viable approach to the development of antiobesity therapeutics.

AB - MK-0493 is a novel, potent, and selective agonist of the melanocortin receptor 4 (MC4R), one of the best-validated genetic targets and considered one of the most promising for the development of antiobesity therapeutics. An ad libitum energy-intake model was qualified with excellent reproducibility: the geometric mean ratio (GMR) with 95% confidence interval (CI) for total energy intake over a period of 24 h for 30 mg sibutramine/placebo was 0.82 (0.76, 0.88), and for 10 mg sibutramine/placebo it was 0.98 (0.91, 1.05). MK-0493 showed a small and marginally significant effect on 24-h energy intake, whereas 30 mg of sibutramine caused a significant reduction in total 24-h energy intake; specifically, the GMR (95% CI) for 30 mg sibutramine/placebo was 0.79 (0.74, 0.85). MK-0493 was associated with modest weight reduction from baseline but had only small, statistically insignificant effects relative to placebo after 12 weeks in a fixed-dose study and also after 18 weeks of stepped-titration dosing. We conclude that agonism of MC4R is not likely to represent a viable approach to the development of antiobesity therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=70450245171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450245171&partnerID=8YFLogxK

U2 - 10.1038/clpt.2009.167

DO - 10.1038/clpt.2009.167

M3 - Article

C2 - 19741604

AN - SCOPUS:70450245171

VL - 86

SP - 659

EP - 666

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -